Replies to post #250635 on Biotech Values

[DewDiligence]

ENGN—(-80%)—reports interim phase-2 data in second-line NMIBC:

https://www.businesswire.com/news/home/20260507845702/en/enGene-Announces-Updated-Interim-Results-From-LEGEND-Pivotal-Cohort

The weak duration of response appears to be the impetus for today’s selloff.